Molecular Profile Detail

Profile Name KRAS exon 2
Gene Variant Detail

KRAS exon2 (unknown)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS exon 2 colon cancer resistant Panitumumab Guideline Actionable Vectibix (panitumumab) is not indicated for use in colon cancer patients with KRAS exon 2 mutations (NCCN.org). detail...
KRAS exon 2 colorectal cancer no benefit Cetuximab + Selumetinib Phase I Actionable In a Phase I trial, the combination of Erbitux (cetuximab) and Selumetinib (AZD6244) demonstrated safety, but minimal efficacy, in patients with metastatic colorectal cancer harboring KRAS exon 2 mutations, with no responses and 36% (5/14) of patients achieving stable disease (PMID: 26666244). 26666244
KRAS exon 2 rectum cancer resistant Cetuximab Guideline Actionable Erbitux (cetuximab) is not indicated for use in rectum cancer patients with KRAS exon 2 mutations (NCCN.org). detail...
KRAS exon 2 colorectal cancer predicted - sensitive Irinotecan + Selumetinib Phase II Actionable In a Phase II study, Selumetinib (AZD6244), in combination with Camptosar (irinotecan), resulted in a partial response in 9.7% (3/31) and stable disease in 51.6% (16/31) of colorectal cancer patients with KRAS exon 2 mutations (PMID: 25322874). 25322874
KRAS exon 2 rectum cancer resistant Panitumumab Guideline Actionable Vectibix (panitumumab) is not indicated for use in rectum cancer patients with KRAS exon 2 mutations (NCCN.org). detail...
KRAS exon 2 colon cancer resistant Cetuximab Guideline Actionable Erbitux (cetuximab) is not indicated for use in colon cancer patients with KRAS exon 2 mutations (NCCN.org). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT03087071 Phase II Panitumumab Trametinib Panitumumab in Combination With Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer Recruiting
NCT03829410 Phase Ib/II Bevacizumab + FOLFIRI + Onvansertib Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation Not yet recruiting